title: Preeclampsia activates 15-lipoxygenase and its metabolite 15-hydroxyeicosatetraenoic acid enhances constriction in umbilical arteries.
abstract: OBJECTIVE
  To compare the differential expression of 15-lipoxygenase (15-LO) isoenzymes, 15-LO-1 and 15-LO-2 in preeclampsia (PE), and normal pregnancy and its metabolite 15-hydroxyeicosatetraenoic acid (15-HETE) on the vasoconstriction of human umbilical artery (HUA) rings.
  
  
  METHODS
  We performed western blotting and isometric tension studies and t-test analysis on data from 6 women with normal pregnancy and 8 women with PE.
  
  
  RESULTS
  Expressions of 15-LO-1 and 15-LO-2 in placentas and HUA rings in PE increased more than that in normal groups (P<0.01). 15-HETE increased HUA rings tension in a dose-dependence manner, which were significantly greater in PE than in normal pregnant controls (P<0.01). However, the constriction of HUA rings was completely eliminated by 2-aminoethoxydiphenyl borate (2-APB) in both normal pregnancy and PE (P<0.01) and attenuated partly by nifedipine in dose-dependence in normal pregnancy (10(-8)mol/L P>0.05; 10(-7), 10(-6)mol/L P<0.05) and in PE (P<0.01).
  
  
  CONCLUSIONS
  PE upregulates 15-LO pathway via 15-HETE, which increased intercellular calcium level to cause constriction of HUA rings.
authors.affiliation: Department of Obstetrics and Gynecology, First Affiliated Hospital of Harbin Medical University, Nangang District, Harbin, Heilongjiang, China.
authors.forename: Yuguang
authors.initials: Y
authors.lastname: Wang
authors.forename: Daling
authors.initials: D
authors.lastname: Zhu
authors.forename: Yuan
authors.initials: Y
authors.lastname: An
authors.forename: Jingxia
authors.initials: J
authors.lastname: Sun
authors.forename: Liying
authors.initials: L
authors.lastname: Cai
authors.forename: Jianhua
authors.initials: J
authors.lastname: Zheng
mesh_terms: D000328:Adult; D001093:Arachidonate 15-Lipoxygenase / Q000378:metabolism*; D015153:Blotting, Western; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation / Q000502:physiology; D005260:Female; D005865:Gestational Age; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000378:metabolism* / Q000494:pharmacology; D066298:In Vitro Techniques; D008423:Maternal Age; D009543:Nifedipine / Q000494:pharmacology; D010920:Placenta / Q000098:blood supply / Q000378:metabolism; D011225:Pre-Eclampsia / Q000378:metabolism / Q000503:physiopathology*; D011247:Pregnancy; D014469:Umbilical Arteries / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology*; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D006893:Hydroxyeicosatetraenoic Acids; D014665:Vasodilator Agents; C025984:15-hydroxy-5,8,11,13-eicosatetraenoic acid; C458528:ALOX15B protein, human; D001093:Arachidonate 15-Lipoxygenase; D009543:Nifedipine